Adverse events640

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 640

Type	Event	Organ system	Group	Affected	At risk	Events
other	Conjunctivitis allergic	Eye disorders	Initial Period - Tralokinumab Q2W	16	602	16
other	Conjunctivitis allergic	Eye disorders	Initial Period - Placebo	3	196	4
other	Conjunctivitis allergic	Eye disorders	Maintenance Period - Tralokinumab Q2W	3	68	3
other	Conjunctivitis allergic	Eye disorders	Maintenance Period - Tralokinumab Q4W	1	76	1
other	Conjunctivitis allergic	Eye disorders	Maintenance Period - Placebo	2	35	2
other	Conjunctivitis allergic	Eye disorders	Maintenance Period - Placebo - Tralokinumab Naive	0	29	0
other	Conjunctivitis allergic	Eye disorders	Open-label Period - Tralokinumab Q2W + Optional TCS	13	563	14
other	Conjunctivitis allergic	Eye disorders	Safety Follow-up	2	595	2
other	Injection site reaction	General disorders	Initial Period - Tralokinumab Q2W	24	602	47
other	Injection site reaction	General disorders	Initial Period - Placebo	0	196	0
other	Injection site reaction	General disorders	Maintenance Period - Tralokinumab Q2W	5	68	13
other	Injection site reaction	General disorders	Maintenance Period - Tralokinumab Q4W	7	76	21
other	Injection site reaction	General disorders	Maintenance Period - Placebo	1	35	1
other	Injection site reaction	General disorders	Maintenance Period - Placebo - Tralokinumab Naive	0	29	0
other	Injection site reaction	General disorders	Open-label Period - Tralokinumab Q2W + Optional TCS	28	563	60
other	Injection site reaction	General disorders	Safety Follow-up	0	595	0
other	Bronchitis	Infections and infestations	Initial Period - Tralokinumab Q2W	11	602	12
other	Bronchitis	Infections and infestations	Initial Period - Placebo	4	196	4
other	Bronchitis	Infections and infestations	Maintenance Period - Tralokinumab Q2W	3	68	3
other	Bronchitis	Infections and infestations	Maintenance Period - Tralokinumab Q4W	7	76	8

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03131648/events

API reference For AI assistants

Adverse events640

Sources 3

Read this list from software.